Scarica l'app Stockscreener
303.77
0.76%
-2.32
Dopo l'orario di chiusura:
303.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$306.09
Aprire:
$306
Volume 24 ore:
965.29K
Relative Volume:
0.96
Capitalizzazione di mercato:
$39.61B
Reddito:
$2.35B
Utile/perdita netta:
$-269.70M
Rapporto P/E:
-145.34
EPS:
-2.09
Flusso di cassa netto:
$-75.39M
1 W Prestazione:
+4.71%
1M Prestazione:
+17.11%
6M Prestazione:
+20.62%
1 anno Prestazione:
+101.91%
Intervallo 1D:
$301.51
$307.85
Intervallo di 1 settimana:
$284.73
$307.85
Portata 52W:
$147.25
$307.85
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
303.77 | 37.83B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
Alnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. Wainwright - Insider Monkey
(ALNY) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alnylam stock soars to all-time high of $304.52 By Investing.com - Investing.com South Africa
Alnylam stock soars to all-time high of $304.52 - Investing.com Australia
JPMorgan lifts Alnylam stock price target to $330 By Investing.com - Investing.com Canada
Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace
RNAi Leader Alnylam Set for Major Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan
Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch By Investing.com - Investing.com India
Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch - Investing.com
Biogen partners with John Maraganore’s new RNAi startup - The Business Journals
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Alnylam supports LGBT community inside and outside the workplace - The Business Journals
3 High-Flying Stocks That Could Soar Even More - AOL.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Alnylam Issues 2024 Corporate Responsibility Report - BioSpace
Alnylam Issues 2024 Corporate Responsibility Report | ALNY Stock News - GuruFocus
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at He - GuruFocus
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at Heart Failure 2025 Congress | ALNY Stock News - GuruFocus
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN
Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in C - GuruFocus
Alnylam posts new data for heart disease drug (ALNY:NASDAQ) - Seeking Alpha
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
High Growth US Tech Stocks To Watch In May 2025 - simplywall.st
Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Promoting A Newly Approved Indication Against Established Competitors - Life Science Leader
Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax - Law360
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now - Reuters
Alnylam shareholders approve executive compensation plan By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - Yahoo
Alnylam shareholders approve executive compensation plan - Investing.com
Alnylam Pharma Re-elects Directors at Annual Meeting - TipRanks
12 Best Growth Stocks to Buy and Hold for the Long Term - Insider Monkey
Hypercholesterolemia Treatment Market Top Companies Study - openPR.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $319.17 Consensus Target Price from Analysts - Defense World
Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress - simplywall.st
Alnylam to present key data on amyloidosis treatments By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Yahoo Finance
Alnylam (ALNY) to Unveil Latest Transthyretin Amyloidosis Data a - GuruFocus
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress - marketscreener.com
Alnylam to Share Progress Across its Transthyretin Amyloidosis F - GuruFocus
Alnylam to present key data on amyloidosis treatments - Investing.com Australia
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
Trend Tracker for (ALNY) - news.stocktradersdaily.com
‘Our bodies are art’: Alnylam campaign uses dance to tell patient’s story - Medical Marketing and Media
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Becker's Hospital Review
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):